V plex sars cov 2 igg panel 22 elisa kit

We measured total binding antibodies against SARS-CoV-2 nucleocapsid (N) and spike (S) receptor binding domain (RBD) in serum using the Roche Elecsys Anti-SARS-CoV-2 and Anti-SARS-CoV-2 S assays, respectively, on a Cobas e601 module analyzer (Roche Diagnostics). Following SARS-CoV-2 infection, both assays should be positive, whereas post-vaccination only the S assay should be positive, allowing identification of convalescent individuals. Both tests are electro-chemiluminescence sandwich immunoassays, and report results in Arbitrary Units (AU)/mL, calibrated against an external standard. For the S assay, the manufacturer indicates that AU values can be considered equivalent to international binding antibody units (BAU) as defined by the World Health Organization [23 ]. For the S assay, sera were tested undiluted, with samples above the upper limit of quantification (ULOQ) re-tested at 1:100 dilution, allowing a measurement range of 0.4 – 25,000 U/mL. We also quantified plasma IgG binding antibodies against RBD using the V-plex SARS-CoV-2 (IgG) Panel 22 ELISA kit (Meso Scale Diagnostics), which features the ancestral (Wuhan) and Omicron RBD antigens, on a Meso QuickPlex SQ120 instrument. Plasma samples were diluted 1:10000 as directed by the manufacturer, with results reported in Arbitrary Units (AU)/mL.

We measured total binding antibodies against SARS-CoV-2 N and spike (S) receptor binding domain (RBD) in serum using the Roche Elecsys Anti-SARS-CoV-2 and Anti-SARS-CoV-2 S assays, respectively, on a Cobas e601 module analyzer (Roche Diagnostics). Following SARS-CoV-2 infection, both assays should be positive, whereas postvaccination only S should be positive, allowing identification of convalescent individuals. Both tests are electrochemiluminescence sandwich immunoassays, and report results in arbitrary units (AU)/mL, calibrated against an external standard. For the S assay, the manufacturer indicates that AU values can be considered equivalent to World Health Organization-defined international binding antibody units [23 ]. For the S assay, sera were tested undiluted, with samples above the upper limit of quantification (ULOQ) retested at 1:100 dilution, allowing a 0.4–25 000 U/mL measurement range. We also quantified plasma immunoglobulin G (IgG) binding antibodies against RBD using the V-plex SARS-CoV-2 (IgG) Panel 22 ELISA kit (Meso Scale Diagnostics), which features the ancestral (Wuhan) and omicron (BA.1) RBD antigens, on a Meso QuickPlex SQ120 instrument. Plasma was diluted 1:10 000 as directed, with results reported in AU/mL.